PMID- 35429289
OWN - NLM
STAT- MEDLINE
DCOM- 20220524
LR  - 20220602
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 42
IP  - 6
DP  - 2022 Jun
TI  - TNFalpha inhibitor biosimilars associated with alopecia areata. Case-based review.
PG  - 1113-1117
LID - 10.1007/s00296-022-05129-w [doi]
AB  - Alopecia areata (AA) is a common non-scaring hair loss associated with many 
      inflammatory and autoimmune disorders. Anti-tumor necrosis factor alpha (TNFalpha) 
      therapy is used to treat many chronic inflammatory disorders and has been proven 
      to be effective and relatively safe. However, several immune-mediated skin 
      reactions have been described with the use of TNFalpha inhibitors, among them AA. In 
      this report, we describe two patients, a 32-year-old woman with ankylosing 
      spondylitis and a 48-year-old man with rheumatoid arthritis who were both treated 
      with SB4 (Benepali((R))), an etanercept biosimilar, and developed AA, 6 and 
      12 months respectively after the initiation of TNFalpha blocker biosimilar. These, 
      are the first two cases of AA development during TNFalpha inhibitors biosimilar. 
      Thus, physicians when dealing with patients treated with these agents, should be 
      aware of possible immune skin reactions, among them AA. To this end, a close 
      follow-up and monitoring is mandatory.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Pelechas, E
AU  - Pelechas E
AUID- ORCID: 0000-0002-9383-5722
AD  - Rheumatology Clinic, Department of Internal Medicine, Medical School, University 
      of Ioannina, 45110, Ioannina, Greece.
FAU - Voulgari, P V
AU  - Voulgari PV
AUID- ORCID: 0000-0002-5193-2284
AD  - Rheumatology Clinic, Department of Internal Medicine, Medical School, University 
      of Ioannina, 45110, Ioannina, Greece.
FAU - Drosos, A A
AU  - Drosos AA
AUID- ORCID: 0000-0002-2232-0326
AD  - Rheumatology Clinic, Department of Internal Medicine, Medical School, University 
      of Ioannina, 45110, Ioannina, Greece. adrosos@uoi.gr.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20220416
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Biosimilar Pharmaceuticals)
RN  - 0 (Immunologic Factors)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - OP401G7OJC (Etanercept)
RN  - Diffuse alopecia
SB  - IM
MH  - Adult
MH  - *Alopecia Areata/chemically induced/drug therapy
MH  - *Biosimilar Pharmaceuticals/adverse effects
MH  - Etanercept/adverse effects
MH  - Female
MH  - Humans
MH  - Immunologic Factors
MH  - Male
MH  - Middle Aged
MH  - Tumor Necrosis Factor-alpha
OTO - NOTNLM
OT  - AS
OT  - Alopecia areata
OT  - Autoimmune skin reaction
OT  - RA
OT  - SB4 (Benepali)
OT  - TNFalpha inhibitors
OT  - TNFalpha inhibitors biosimilar
EDAT- 2022/04/17 06:00
MHDA- 2022/05/25 06:00
CRDT- 2022/04/16 12:02
PHST- 2022/03/03 00:00 [received]
PHST- 2022/03/29 00:00 [accepted]
PHST- 2022/04/17 06:00 [pubmed]
PHST- 2022/05/25 06:00 [medline]
PHST- 2022/04/16 12:02 [entrez]
AID - 10.1007/s00296-022-05129-w [pii]
AID - 10.1007/s00296-022-05129-w [doi]
PST - ppublish
SO  - Rheumatol Int. 2022 Jun;42(6):1113-1117. doi: 10.1007/s00296-022-05129-w. Epub 
      2022 Apr 16.